Featured Courses
Challenges in ATTR Amyloidosis: An Expert Debate
- 1.00
Published:
Learning objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
- Recall the limitations of existing therapies for ATTR-CM
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
TAVI Head-To-Head: Design, Data and Directions for Clinical Practice
- 1.00
Published:
Learning objectives
- Recall TAVI SMART trial data and the implications on clinical practice
- Describe novel valve designs and the impact on long-term performance
- Develop an expert-led approach to improving equitable access to TAVI
TAVI – Is Lifetime Patient Management the Alpha to Omega of Contemporary Practice?
- 1.00
Published:
Learning objectives
- Evaluate the factors influencing coronary access in different valve designs
- Formulate strategies to optimise coronary access based on valve characteristics
- Evaluate the role of valve design in reducing pacemaker implantation rates and enhancing future coronary access
- Learn the step-by-step process for achieving optimum implant depth during TAVI
- Apply guidelines and best practices for achieving and confirming optimum implant depth in TAVI procedures
An Expert Approach to Cardio-Renal Protection in CKD
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
The Advancing Management of Transthyretin Amyloidosis
- 1.00
Published:
Learning objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023
- 1.00
Published:
Learning objectives
- Recall guideline updates relevant to the use of disease modifying agents in hypertrophic cardiomyopathy
- Identify patients who, according to guidelines, may benefit from emerging disease modifying therapies prior to septal ablation therapy or being managed by symptom control alone
- Discuss long-term management strategies for patients receiving myosin inhibitor therapy
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
- 1.00
Published:
Learning objectives
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
The Clinical Evidence Behind Pulse Field Ablation
- 1.00
Published:
Learning objectives
- Identify limitations of current ablation technologies
- Recall the advantages of pulse field ablation over other technologies
- Summarise the design, efficacy and safety findings of relevant clinical trial data evaluating the efficacy and safety of pulse field ablation technology
- Compare different PFA systems and emerging technologies
- Evaluate the evolving landscape of pulse field ablation technologies
TIO 2023 – Keynote & Debate
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
Available Courses
A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
- 1.00
Published:
Learning objectives
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
Advanced Approaches to Combined Epicardial and Endocardial Strategies – From New Consensus to Practice
- 1.00
Published:
Learning objectives
- Identify patient populations who may benefit from hybrid ablation
- Summarise the existing rationale and evidence for hybrid ablation beyond atrial fibrillation
- Understand how to integrate left atrial appendage exclusion in atrial ablation approaches
- Examine key aspects of new consensus recommendations for hybrid ablation
Advancing Patient Care in Hypertrophic Cardiomyopathy
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
An Expert Approach to Cardio-Renal Protection in CKD
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
Challenges in ATTR Amyloidosis: An Expert Debate
- 1.00
Published:
Learning objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
- Recall the limitations of existing therapies for ATTR-CM
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2.00
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Most Recent
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
Advancing Patient Care in Hypertrophic Cardiomyopathy
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice